Zhe Ji is an Assistant Professor in the Department of Biomedical Engineering at McCormick School of Engineering and the Department of Pharmacology at Feinberg School of Medicine, Northwestern University. His research integrates computational and experimental genomics to study gene transcription and RNA translation in cell fate commitment and oncogenic processes, aiming to develop precision medicine strategies. **Education**: Postdoctoral Fellow in Cancer Systems Biology, Harvard Medical School Postdoctoral Fellow in Computational Biology, Broad Institute of MIT and Harvard Ph.D. in Computational Genomics, Rutgers University B.S. in Biotechnology, Nanjing University, China **Research Focus**: Keywords include Data Science, Computational Biology, Functional Genomics, RNA, Cancer, Inflammation, and Machine Learning. The lab explores regulatory mechanisms underlying disease, with a focus on translational control, cancer metastasis, and inflammatory networks. **Grants & Advising**: No specific grants or student advisees listed. The lab emphasizes collaborative projects and computational-experimental approaches. **Lab Affiliations**: Zhe Ji’s lab is part of Northwestern’s interdisciplinary environment, bridging engineering and medicine to advance genomic technologies and therapeutic strategies.
Prof. Waldemar Kolanus leads the Molecular Immunology and Cell Biology department at the University of Bonn's Life & Medical Sciences Institute (LIMES) . His research bridges immunoregulation , stem cell dynamics , and metabolic stress responses in immune cells. Unit 2 member at LIMES Principal investigator in SFB 704 and ImmunoSensation Cluster Leads a multidisciplinary lab with postdocs, PhD students, and technical staff His work focuses on intracellular signaling pathways connecting immune activation to tissue homeostasis, particularly through: Cytohesin proteins in integrin-mediated adhesion and migration TRIM71 in stem cell regulation and congenital hydrocephalus High-salt environments affecting macrophage function Publication trends show expertise in immune cell migration , genetic models , and chemical inhibition , with frequent use of mice and zebrafish for in vivo studies. Key articles explore: TRIM71's dual role in auditory development and germ cell maintenance Cytohesin family's Golgi regulation and insulin signaling Ruxolitinib's off-target migration inhibition of dendritic cells Contact details: Address: LIMES Institute, Carl-Troll-Straße 31, Bonn Email: kolanus.sekretariat@uni-bonn.de Phone: +49 228 73-62788
Dr. Vadim Backman is the Sachs Family Professor of Biomedical Engineering and Medicine at Northwestern University's McCormick School of Engineering and Applied Sciences and Feinberg School of Medicine. He holds additional roles as Professor of Medicine (Hematology/Oncology) and Biochemistry and Molecular Genetics, Associate Director of Research Technology and Infrastructure at the Robert H. Lurie Comprehensive Cancer Center, and Director of the Center for Physical Genomics and Engineering. He earned his Ph.D. in Medical Engineering from Harvard-MIT and M.S./B.S. in Physics from St. Petersburg Polytechnic Institute. His research focuses on physical and biological science intersections, developing nanoscale imaging and computational technologies to study chromatin dynamics and their role in disease. Key areas include cancer diagnostics/therapeutics, chromatin engineering, and genome nanoimaging. Dr. Backman has published over 230 papers, holds 20+ patents, and leads large-scale projects like NCI Bioengineering Research Partnerships. Education: Ph.D. (Harvard-MIT), M.S. (MIT), M.S./B.S. (St. Petersburg Polytechnic Institute) Affiliations: PhD Programs in Applied Physics and Interdisciplinary Biological Sciences Research emphasizes chromatin's role in disease, with clinical translation for diagnostics and therapy. His lab develops technologies like nano-CHIA and ChromSTEM, advancing understanding of genomic organization and epigenetic regulation. Awards include the Cozzarelli Prize and MIT Technology Review's Top 100 Innovators. Awards: Cozzarelli Prize (2017), AIMBE Fellowship (2009), NSF CAREER Award (2003) Grants and collaborations include managing multi-investigator projects and co-founding biotech companies. Courses taught: BME 302 (Quantitative Systems Physiology), BME 429 (Advanced Physical and Applied Optics).
Amy Catherine Rowat is a full Professor in the Department of Integrative Biology and Physiology at UCLA's College of Letters and Science. She directs an interdisciplinary research program that integrates mechanobiology, microfluidics, cancer biophysics and food engineering to understand how physical forces shape cell behavior and to develop sustainable biotechnologies. Education & Affiliations: Professor, Department of Integrative Biology and Physiology, UCLA Member, UCLA College of Letters and Science Research Interests: Rowat's group deciphers how mechanical properties of cells and their nuclei influence disease progression and therapeutic response. Using high-throughput microfluidic deformability cytometry, her team discovered that cancer cells become stiffer and more invasive upon β-adrenergic signaling, linking stress hormones to metastatic potential. Parallel efforts focus on nuclear envelope mechanics, showing that histone H1.0 and transient nuclear deformation modulate chromatin structure and cell reprogramming. Beyond biomedicine, Rowat pioneers biophysical approaches for sustainable food production. She engineers edible scaffolds and emulsion-templated microcarriers to culture meat at scale, demonstrating spontaneous fusion of adipogenic and myogenic microtissues into marbled steak-like constructs. Recent Article Trends (2020-2025): Her latest publications reveal a cohesive trajectory: coupling mechanobiology to epigenetic regulation (viscoelastic matrix enhances chromatin remodeling), advancing single-cell mechanical phenotyping (optomagnetic arrays, high-throughput screens), translating findings to cancer therapy (β-blockers to sensitize chemotherapy) and expanding engineered foods (scalable cultured-meat bioprocessing). Funding & Awards: NIH R21 CA245667 (PI) – Repurposing beta-blockers to improve chemotherapy response (2021-2023) Laboratory & Teams: Rowat leads an active research laboratory at UCLA that trains graduate students and postdocs at the intersection of physics, engineering and biology. The lab maintains collaborations across UCLA Engineering, Jonsson Comprehensive Cancer Center, and external partners in food science and biotechnology companies.
Song Li is a Chancellor's Professor in the Department of Bioengineering at the University of California, Los Angeles (UCLA) and serves as Associate Dean for Graduate and Professional Education. His research intersects engineering, biology, and medicine to advance cell engineering, mechanobiology, and immunoengineering. Education: B.S. and M.S. from Peking University; Ph.D. in Bioengineering from University of California, San Diego. Li Lab focuses on mechanotransduction, cell reprogramming for regenerative medicine, and immunoengineering. Research emphasizes translating discoveries into biomedical applications through multidisciplinary collaborations. The lab's recent work in Nature Materials explores how nuclear deformation impacts epigenetic states and cell reprogramming. Publications reflect expertise in mechanobiology, regenerative medicine, and bioengineering technologies. Scientific Awards: Chancellor's Professorship, IAMBE Fellow, Biomedical Engineering Society Fellow, AIMBE Fellow, and UC Systemwide Bioengineering Symposium keynote. Li Lab fosters innovation in cell engineering and immunoengineering, with grants including coronavirus vaccine booster research. The lab promotes diversity, equity, and inclusion in collaborative biomedical discovery.
Professor Faye Rogers serves as Professor of Therapeutic Radiology at Yale University School of Medicine, holding multiple leadership positions including Associate Cancer Center Director for YCC Collaborative Excellence, Vice Chair for Collaborative Excellence in Therapeutic Radiology, Associate Director of the Yale MD-PhD Program, and Director of the Yale BioMed Amgen Scholars Program. Her work bridges radiation oncology, DNA repair mechanisms, and cancer therapeutics within Yale's comprehensive cancer research ecosystem. PhD from University of Maryland at Baltimore (1998) Postdoctoral Fellow at Yale School of Medicine Dr. Rogers' research focuses on the intersection of DNA repair mechanisms and cancer therapeutics, with particular expertise in triplex DNA structures, genomic instability, and targeted cancer therapies. Her work explores how DNA damage responses can be leveraged for therapeutic benefit, especially in breast neoplasms and other malignancies. Through her leadership in the DNA Damage and Genome Integrity program, she investigates novel approaches to disrupt cancer cell survival mechanisms while sparing healthy tissue. Her research has significant implications for radiation oncology, particularly in developing more precise and effective radiation-based treatments. Analysis of Dr. Rogers' publication record reveals a consistent trajectory in DNA repair mechanisms and cancer therapeutics, with increasing focus on translational applications. Her work demonstrates expertise in triplex DNA structures, RAD51 inhibition, and synthetic lethality approaches. Recent publications show a shift toward more clinically applicable research, particularly in targeting DNA repair pathways in specific cancer subtypes like IDH1-mutant cancers and PTEN-deficient glioblastomas. Her collaborative work with Peter Glazer and others demonstrates strong interdisciplinary connections between radiation oncology, molecular biology, and drug development. Leadership in Diversity, Equity & Inclusion Award (Yale School of Medicine, 2022) Translational Science Research Prize (Yale Cancer Center, 2022) Kingsley Fellowship in Medical Research Carl Storm Underrepresented Minority Fellowship NCI Research Supplement to Promote Diversity in Health-Related Research As Associate Director of the Yale MD-PhD Program and Director of the Yale BioMed Amgen Scholars Program, Dr. Rogers plays a pivotal role in mentoring the next generation of physician-scientists and supporting underrepresented minorities in biomedical research. Her leadership in collaborative excellence initiatives demonstrates commitment to fostering interdisciplinary research teams across Yale's scientific ecosystem. Through the YCC Collaborative Excellence program, she has secured significant funding for innovative cancer research that bridges basic science and clinical applications, particularly in the areas of DNA repair targeting and radiation oncology. Dr. Rogers leads research within Yale's Therapeutic Radiology department, with strong connections to the Radiobiology program and the Yale Cancer Center. Her work is integrated with the Program in Translational Biomedicine and the Yale Combined Program in the Biological and Biomedical Sciences. Through the BioMed Amgen Scholars Program, she provides critical research opportunities for undergraduate students, particularly those from underrepresented backgrounds, fostering talent in DNA repair research and cancer therapeutics.
Moira Whyte serves as Sir John Crofton Professor of Respiratory Medicine and Head of Edinburgh Medical School at the University of Edinburgh, while directing the MRC University of Edinburgh Centre for Inflammation Research. Her leadership spans clinical academia and major research initiatives focused on respiratory pathophysiology. Her educational background includes a 1st Class B.Sc. (1981), M.B., B.S. (1984), and Ph.D. (1993) from the University of London, complemented by professional qualifications: M.R.C.P. (1987), F.R.C.P. (1998), and F.Med.Sci. (2005) from the Academy of Medical Sciences. Whyte's research centers on neutrophil biology, macrophage function, and hypoxia signaling pathways in respiratory diseases. Her work explores how oxygen-sensing mechanisms like HIF pathways regulate immune cell function in COPD, pulmonary fibrosis, and bacterial infections, with particular focus on cellular metabolism and inflammation resolution. Analysis of her 15 most recent publications reveals consistent focus on neutrophil and macrophage biology within respiratory diseases, with growing emphasis on metabolic regulation of immune responses. Her work bridges basic science (using zebrafish models) with clinical applications, particularly in COPD and pulmonary fibrosis. Her scientific recognition includes: 2014 OBE for Services to Respiratory Medicine 2014 Foundation Fellow of the European Respiratory Society 2005 Fellow, Academy of Medical Sciences 2002 Tudor Edwards Lecturer of the Royal College of Physicians 1994 Wellcome Trust Advanced Fellowship 1989 MRC Clinical Training Fellowship Whyte directs substantial research funding, including a £6.4M Wellcome Trust Clinical PhD Programme (ECAT-Plus) and multiple grants investigating macrophage function in COPD, hypoxia pathways in pulmonary fibrosis, and neutrophilic inflammation regulation. Her collaborative approach is evident in multi-institutional projects like the EME-TIPAC study on pulmonary fibrosis. As Director of the MRC Centre for Inflammation Research, she leads a multidisciplinary team investigating fundamental mechanisms of inflammation across multiple disease contexts, with particular strength in respiratory immunology and translational applications.
Keisuke Ishihara is an Assistant Professor in the Department of Computational and Systems Biology at the University of Pittsburgh School of Medicine. His research focuses on engineering human brain and cardiac organoids using genetic, chemical, and computational approaches to uncover novel regulatory mechanisms and physical principles underlying tissue development. His lab is located at Biomedical Science Tower 3, with an office in room 10020A. Dr. Ishihara holds a PhD in Systems Biology from Harvard University. His work bridges synthetic biology, developmental biology, and biophysics to address fundamental questions in organogenesis and cellular morphogenesis. Recent research highlights include studies on BMP-mediated neural tube patterning in organoids and the biophysical dynamics of microtubule assemblies in large cells. Publications from his lab emphasize interdisciplinary approaches to understand cell size scaling, mitotic spindle dynamics, and self-organization in synthetic tissues. His team has contributed to advancements in organoid technology, uncovering dormant genetic programs and physical principles governing tissue architecture. Laboratory activities are centered at the University of Pittsburgh, collaborating with the School of Medicine's computational and systems biology initiatives. For more details, visit his lab website linked below.
Anders Sejr Hansen is an Assistant Professor of Biological Engineering at MIT, leading the Hansen Lab focused on understanding 3D genome structure and its functional implications. He holds a PhD from Harvard University and completed postdoctoral training at UC Berkeley. His research integrates advanced imaging, genomics, and computational methods to study chromatin dynamics, enhancer-promoter interactions, and their roles in gene regulation across health and disease. Education: Bachelor's/Master's in Chemistry, University of Oxford (2010) PhD in Chemistry and Chemical Biology, Harvard University (2015) Postdoctoral Research, UC Berkeley (2015–2020) Research Interests: His work spans molecular mechanisms of genome organization, development of novel microscopy techniques (e.g., MINFLUX, expansion microscopy), and computational models for 3D genomics. Key areas include chromatin dynamics, loop extrusion by cohesin/condensin, and the impact of 3D structure on gene expression in cancer and aging. Awards: NIH K99 Pathway to Independence Award (2019) NIH Director’s New Innovator Award (2020) Pew-Stewart Scholar for Cancer Research (2021) NSF CAREER Award (2024) NIH Director’s Transformative Research Award (2024) Advising & Grants: Hansen mentors PhD students and postdocs, including notable advisees Viraat Goel and Domenic Narducci. His lab has secured major grants from NIH, NSF, and private foundations, supporting interdisciplinary projects in imaging, genomics, and synthetic biology. Labs/Teams: The Hansen Lab at MIT collaborates with institutions globally, advancing technologies like Region Capture Micro-C (RCMC) and deep learning models (e.g., Cleopatra) for high-resolution genome mapping. The lab also explores synthetic biology approaches to engineer genome structures.
G. Petur Nielsen, MD is a Professor of Pathology at Harvard Medical School and serves as Subspecialty Head, Bone and Soft Tissue Pathology at Massachusetts General Hospital . With a clinical focus on bone and soft tissue tumors, his expertise spans diagnostic pathology, molecular genetics of neoplasms, and ancillary testing applications. Research interests center on Pathology and biology of bone/soft tissue tumors Molecular genetics of bone and soft tissue neoplasms Chordoma and sarcoma research Epithelioid vascular tumor differentiation Mesenchymal tumors of the female genital tract His work includes landmark studies on tumor misdiagnosis rates, immunohistochemical profiling, and genomic analysis of chordomas. Scientific contributions appear in leading journals like Nature and American Journal of Surgical Pathology , with major emphasis on Molecular tumor classification Mutational signature analysis Translational oncology Diagnostic accuracy improvement Genomic instability mechanisms
Dr. Jun Wu is an Assistant Professor in the Department of Molecular Biology at UT Southwestern Medical Center. He holds a PhD in Life Science from the University of Tennessee and completed postdoctoral training at the University of Southern California and the Salk Institute. His research focuses on stem cell biology, genome editing, and interspecies chimeras to advance regenerative medicine and developmental biology. Education: Bachelor of Medicine, Shandong University School of Medicine (China) PhD in Life Science, University of Tennessee (2013) Postdoctoral Fellowships: USC (2013-2015) and Salk Institute (2015-2017) Research Interests: Generation of pluripotent stem cells with distinct molecular/phenotypic features Development of interspecies blastocyst complementation systems Modeling peri-implantation human development using stem cell embryo models Study of species-specific developmental barriers and evolutionary biology Application of chimeras to study cancer resistance and organ size determination Lab Activities: The Wu Lab develops stem cell models to study mammalian development and create regenerative therapies. Key projects include: Creation of interspecies chimeras (human-monkey, rat-mouse) Development of blastoids and peri-gastruloids Analysis of species-specific cell competition mechanisms Engineering cross-species organogenesis systems Grant Activities: Focuses on NIH-funded projects related to stem cell biology, interspecies chimerism, and regenerative medicine applications. Collaborates with institutions like Salk Institute and University of California campuses. Lab Team: Includes postdoctoral researchers like Dr. Yi Ding and a multidisciplinary team of molecular biologists, bioengineers, and computational biologists.
Kathryn E. Dickerson, M.D., M.S.C.S., is an Assistant Professor in the Department of Pediatrics at UT Southwestern Medical Center, specializing in the Division of Hematology and Oncology. She holds dual appointments as a 2015 Translational Research Scholar in the UTSW Center for Translational Medicine and as an NIH KL2 scholar. Her clinical focus is pediatric hematology, emphasizing bone marrow failure disorders, cancer predisposition syndromes, and thalassemia/dyserythropoietic anemias. Her research investigates epigenetic regulation of myeloid malignancies, clonal hematopoiesis in childhood cancer survivors, and molecular mechanisms underlying acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myeloproliferative disorders (MPD). Education: Bachelor's in Biochemistry (Indiana University), minor in Spanish Medical degree (Indiana University School of Medicine) Masters of Science in Clinical Sciences (UT Southwestern Center for Translational Medicine) Training: Pediatric residency with research pathway (Ohio State University/Nationwide Children’s Hospital) Pediatric hematology-oncology fellowship (UT Southwestern) Dr. Dickerson’s research bridges basic science and clinical practice, leveraging CRISPR-based epigenetic editing, genomic analysis, and translational studies to understand disease mechanisms. Key projects include interrogating enhancer dysregulation in leukemia, studying metabolic reprogramming in cancers, and evaluating clonal hematopoiesis in survivors of childhood cancers. Her work has advanced understanding of EZH2’s role in AML and identified therapeutic vulnerabilities in myeloid malignancies. Awards: 2015 Translational Research Scholar (UTSW Center for Translational Medicine) NIH KL2 Career Development Award Grants/Initiatives: NIH-funded investigator-initiated study on clonal hematopoiesis Industry/consortia-sponsored trials for bone marrow failure and rare blood disorders She collaborates with the Children’s Research Institute and North American Pediatric Aplastic Anemia Consortium, contributing to clinical trials and translational initiatives. Her lab focuses on developing biomarkers for disease severity (e.g., immature platelet fraction in pediatric COVID-19) and therapeutic strategies targeting epigenetic dependencies in leukemia.
Eduardo N. Chini, M.D., Ph.D., is a Professor at Mayo Clinic with primary and joint appointments in the Department of Anesthesiology and Perioperative Medicine and the Department of Cancer Biology. He is based in Rochester, Minnesota, and leads a research program focused on NAD metabolism, aging, and their roles in diseases such as cancer, obesity, and kidney disease. Education: BS in Biology, Centro Educacional de Niteroi-RJ MD, Universidade do Rio de Janeiro PhD in Biological Chemistry, Universidade do Rio de Janeiro Fellow, Department of Physiology and Biophysics, Mayo Clinic Resident in Anesthesiology, Mayo Clinic College of Medicine Research Interests: Eduardo N. Chini's research investigates the central role of nicotinamide adenine dinucleotide (NAD) in cellular metabolism, aging, and disease. His lab has made foundational discoveries in NAD catabolism, identifying CD38 as the primary enzyme regulating NAD levels in mammals. His work explores SIRT1 regulation via CD38 and DBC1, NAD metabolism in cancer, and its implications in polycystic kidney disease. He is particularly interested in how NAD signaling influences aging, metabolic syndrome, and organ dysfunction. Recent Research Trends: His recent publications (2023–2025) reveal a strong focus on the role of CD38 in aging, immune function, and tissue metabolism. Key themes include NAD+ depletion triggering inflammatory responses, CD38 inhibition as a therapeutic strategy for cardiotoxicity and metabolic aging, and the interplay between senescence, stem cell function, and mitochondrial health. His work increasingly integrates translational models with molecular mechanisms in aging and cancer. Scientific Awards: Florida Investigator of the Year, Mayo Clinic (2024) Glenn/AFAR Breakthroughs in Gerontology Award (2007) Edward C. Kendall Award, Mayo Clinic Alumni Association (2002) Directors Award for Aging Research, Kogod Center on Aging (2018) Distinguished Scientist Seminar Series, Georgetown Medical School (2022) Grants and Leadership: Dr. Chini is a co-Principal Investigator on multiple NIH-funded grants, including projects on CD38 in scleroderma, CLL, and male reproductive aging. He is Co-Director of the Mayo Clinic Mitochondrial Care Center and Associate Director of the Robert and Arlene Kogod Center on Aging. He has served on numerous national review panels and advisory councils, including the NIH Hepatobiliary Pathophysiology Study Section and AFAR's National Scientific Advisory Council. Labs and Teams: Dr. Chini leads a research laboratory at Mayo Clinic focused on NAD metabolism and aging. His team collaborates extensively with experts in cancer biology, mitochondrial medicine, and aging research. He is affiliated with the Mayo Clinic Comprehensive Cancer Center, the Kogod Center on Aging, and the Robert M. and Billie Kelley Pirnie Translational PKD Center.
Andrew Godwin is a Professor at the University of Kansas Medical Center , where he serves as the Chancellor’s Distinguished Chair in Biomedical Sciences and Director of Molecular Oncology in the Department of Pathology and Laboratory Medicine. He is also the Deputy Director of the NCI-designated University of Kansas Cancer Center and the Founding Director of the Kansas Institute for Precision Medicine and Biospecimen Shared Resource . Dr. Godwin is a leader in translational research and precision medicine , with a focus on molecular oncology , biomarker discovery , and genomic diagnostics . His work bridges basic and clinical science to improve cancer patient care, particularly in ovarian cancer , Ewing sarcoma , and breast cancer . He has contributed over 230 ovarian cancer-related publications and pioneered studies linking the PI3K/AKT pathway to cancer treatment targets. His research program encompasses liquid biopsies using extracellular vesicles , molecular therapeutics , companion diagnostics , and clinical trial validation . He leads the Biomarker Discovery Laboratory and has secured over $250M in extramural funding , including a $11.4M NIH grant for precision medicine initiatives. His team has developed CELLSEARCH® , the first FDA-cleared test for circulating tumor cells. Notable awards include the Dolph C. Simons, Sr. Higuchi Award (2020), Outstanding Mentorship in Pathology Award (2024), and multiple mentoring accolades from KU. He has mentored over 150 trainees across career stages and leads a multidisciplinary lab with expertise in genomics , proteomics , and bioengineering . Academic Roles: Chancellor’s Distinguished Chair in Biomedical Sciences Director, Molecular Oncology, Pathology and Laboratory Medicine Deputy Director, KU Cancer Center Founding Director, Kansas Institute for Precision Medicine Adjunct Professor, Bioengineering Program, University of Kansas Scientific Awards: KUMC Achievement Award for mentoring postdocs (2014) Chancellor’s Club Award for Research (2018) Dolph C. Simons, Sr. Higuchi Award (2020) KU Excellence in Mentoring Award (2021) Outstanding Mentorship in Pathology (2024) Key Research Themes: Extracellular vesicles as liquid biopsy tools Molecular mechanisms of sarcoma and breast cancer Genomic diagnostics and precision oncology Clinical trial biomarker validation Biospecimen repository leadership
Jerry W. Shay is a Professor in the Department of Cell Biology at UT Southwestern Medical Center, holding the Southland Financial Corporation Distinguished Chair in Geriatric Research. He also serves as Associate Director for Education and Training at the Harold Simmons Comprehensive Cancer Center. His research focuses on telomere biology, aging, and cancer therapy development, with an emphasis on targeting telomerase in cancer treatment and understanding age-related disease mechanisms. Shay earned his BA in Zoology/Cell Biology from the University of Texas at Austin (1966), MA in Cell Biology from the University of Kansas (1968), and PhD in Developmental Biology from the University of Colorado Boulder (1975). He joined UT Southwestern in 1975, advancing from Assistant/Associate Professor to full Professor in 1993. His research interests include telomere dysfunction-induced anti-tumor immunity, cancer therapy resistance, and the role of telomerase in cellular aging. Key projects involve developing therapies like 6-thio-dG, which targets telomerase-dependent cancers, and studying the interplay between environmental toxins and colorectal carcinogenesis. Awarded numerous honors including the UT Regent’s Outstanding Teaching Award (2012) and the Piper Professorship (2013), Shay has contributed to over 30 patents, including methods to detect telomerase activity and compounds targeting cancer cell adhesion. His lab collaborates with companies like Maia Biotechnology and Reata Pharmaceuticals to translate research into clinical applications. Shay’s work bridges basic science and translational research, with ongoing projects in radiation-induced cancer progression, immune modulation in cancer treatment, and telomere measurement technologies like the TeSLA assay.
